Enlivex Acquires 3 Billion RAIN Tokens at 62% Discount
Nasdaq-listed pharmaceutical company Enlivex (ENLV) has significantly expanded its digital asset treasury, acquiring 3.03 billion RAIN tokens for $10 million. The purchase, announced on March 24, 2026, was executed at a price of $0.0033 per token, representing a 62% discount to the token's closing price on March 22. This move was funded by a $21 million debt financing agreement with institutional fund manager The Lind Partners, which provided net proceeds of approximately $18.7 million and closed on March 23.
The acquisition deepens Enlivex's position in the decentralized prediction market protocol, as the purchase price is notably lower than the token's recent trading range of $0.008 to $0.01 over the last 30 days. Shai Novik, Executive Chairman of Enlivex, highlighted the strategic value of the deal.
We are continuing to execute our prediction markets treasury strategy... allowing us to acquire approximately three billion additional RAIN tokens, at a purchase price of $0.0033 per token... an attractive purchase price.
— Shai Novik, Executive Chairman, Enlivex
Dual Strategy Signals Confidence with $20M Share Buyback
Alongside the crypto acquisition, Enlivex unveiled a dual strategy to enhance shareholder value. The company's board approved a $20 million share repurchase program for its own ordinary shares. This action signals management's belief that its stock is undervalued, a sentiment echoed by CEO Oren Hershkovitz, who stated that Enlivex's shares represent a "substantial discount to the market value of our treasury and treasury-related assets." This suggests a conviction that the market is undervaluing both its core pharmaceutical business and its growing crypto holdings.
Further cementing its long-term commitment, Enlivex also secured an extension on its option to buy more tokens. The Rain Foundation extended the company's right to acquire up to an additional 272.1 billion RAIN tokens at the same preferential price of $0.0033. The option's deadline was pushed from November 30, 2026, to December 31, 2027, giving Enlivex a prolonged opportunity to scale its treasury operations at a fixed, discounted rate.
